ACESO PARTNERSHIPS

Advancing science Together

We collaborate with scientific, clinical, strategic, and investment partners who share our mission to advance meaningful therapies for cystic fibrosis patients with unmet needs.

01 · PARTNERSHIP THESIS

Better together.

We partner with scientists, clinicians, patient-focused organizations, and strategic collaborators who share our commitment to advancing meaningful therapies for cystic fibrosis patients with unmet needs.

WE LOOK FOR

Partners with deep scientific insight, clinical expertise, translational capabilities, or strategic resources aligned with our mission to restore CFTR function and expand treatment possibilities.

WE OFFER

A focused dual-therapy platform, disciplined scientific execution, and a collaborative approach designed to move promising ideas from biological rationale toward therapeutic impact.

02 · PARTNER LOGO WALL

Who we work with.

We collaborate with research institutions, clinical experts, foundations, strategic partners, and mission-aligned investors working to advance cystic fibrosis science and therapeutic development.

PARTNERSHIPS

Partnering to accelerate the next generation of CF therapeutics

ACESO is open to scientific, clinical, investment, and strategic partnerships aligned with our mission to address unmet needs in cystic fibrosis.

Research Collaboration

Research collaborations

Joint scientific programs with academic groups, foundations, and CF research consortia advancing CFTR biology.

Clinical Development Partners

Clinical development partners

Working with clinical investigators, CROs, and CF reference centers to advance candidates toward the clinic.

Strategic & Investor

Strategic & investor partnerships

Engaging biotech, pharma, and investors aligned with our long-term mission to expand CF treatment options.

Research

Research collaborations

Research

Since December 2025, Aceso collaborates with The University of Montpellier. A leading French research university with strong expertise in life sciences, health, and translational medicine. PhyMedExp (Physiology and Experimental Medicine of the Heart and Muscles) is a joint unit of INSERM, CNRS, and the University of Montpellier, focusing on cardiovascular, muscle, and respiratory research from basic science to clinical applications.

Development

Through its collaboration with WuXi, Aceso Therapeutics aims to accelerate and secure ACT-101’s CMC development, supported by WuXi’s recognized global expertise and comprehensive capabilities in pharmaceutical development.

By collaborating with ILIFE, Aceso Therapeutics aims to anticipate the design of ACT-101’s clinical study synopsis and secure this next development stage by leveraging the recognized clinical expertise of ILIFE’s team.

By collaborating with L2D, Aceso Therapeutics aims to advance ACT-101’s regulatory development efficiently and securely, supported by the recognized expertise of L2D’s team.

By partnering with NanoPharm company of Aptar Pharma group, Aceso Therapeutics aims to accelerate and secure the development of ACT-101 while reinforcing the program’s unique technological value and inhalation delivery expertise.

LET'S TALK

Partner with us to redefine cystic fibrosis care.

We welcome conversations with collaborators, investors, and strategic partners aligned with our mission.

CASE STUDIES

Selected collaborations

A look at how ACESO partners with academic, strategic, and research collaborators to advance science for underserved CF populations.

ACADEMIC · SINCE 2021

Advancing CFTR restoration through academic collaboration.

A focused research partnership exploring complementary mechanisms to restore CFTR function for underserved cystic fibrosis mutation classes.

STRATEGIC · SINCE 2022

Translating dual-therapy science into preclinical validation.

A development-focused collaboration supporting the progression of dual-therapy concepts toward structured preclinical evidence and program readiness.

RESEARCH · SINCE 2023

Building pathways for difficult-to-treat CF populations.

A scientific collaboration designed to identify mutation-class opportunities and accelerate therapeutic strategies for patients with limited options.

Get in touch

Ready to explore the science
behind ACESO?

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

contact@aceso-therapeutics.com

Headquarters

Advancing science Together

Better together.

Who we work with.